Premarket Tobacco Product Applications
Before a new tobacco product can be legally marketed, FDA must issue an order permitting marketing of that product. To issue a premarket tobacco product application (PMTA) marketing order, FDA must evaluate that product based on a public health standard that considers the risks and benefits of the product to the population as a whole, including tobacco product users as well as non-users.
Commonly Asked Questions:
- When should I use the premarket tobacco product application (PMTA) process?
- How do I demonstrate the new tobacco product is appropriate for the protection of public health?
- What information is needed in my PMTA?
- When should I submit my PMTA?
- How do I submit my PMTA?
- What happens after I submit my PMTA?
- Is there information available to help me in the premarket tobacco product application process?
- How do I request a meeting with FDA?
A PMTA may be submitted when seeking authorization for any new tobacco product. There are other pathways for marketing authorizations. If you are not sure what pathway is appropriate for your product, use the interactive tool.
How Do I Demonstrate that the New Tobacco Product Is Appropriate for the Protection of Public Health?
PMTAs must provide scientific data to demonstrate that marketing the new tobacco product is appropriate for the protection of public health. This is determined by evaluating the risks and benefits to the population as a whole including users and non-users. Such demonstration shall take into account the increased or decreased likelihood that existing tobacco users will stop using such products, and the increased or decreased likelihood that those who do not use tobacco products will start using them.
Your PMTA must include the following information, as required by Section 910(b)(1) of the FD&C Act:
- full reports of all information, published or known to, or which should reasonably be known to, the applicant, concerning investigations that have been made to show the health risks of such tobacco product and whether such tobacco product presents less risk than other tobacco products;
- a full statement of the tobacco product's
- properties, and
- principle(s) of operation;
- a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and, when relevant, packing and installation of such tobacco product;
- an identifying reference to any tobacco product standard, under section 907, which would be applicable to any aspect of such tobacco product, and either adequate information to show that such aspect of such tobacco product fully meets such tobacco product standard or adequate information to justify any deviation from such standard;
- such samples of such tobacco product and of components thereof as the Secretary may reasonably require;
- specimens of the labeling proposed to be used for such tobacco product; and
- other information relevant to the subject matter of the application as the Secretary may require.
For more information, see Guidance: Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS) (2019) and Draft Guidance: Applications for Premarket Review of New Tobacco Products (2011).
The applicant must obtain an order from FDA authorizing marketing of the new product before it can be introduced or delivered for introduction into interstate commerce as per Section 910(a)(2) of the FD&C Act. One way to receive an order is through a PMTA. To receive a PMTA marketing order, an application must be submitted by the applicant, reviewed by FDA, and determined to be appropriate for the protection of public health.
A new tobacco product is either a product commercially marketed in the United States after February 15, 2007, or any modification to a tobacco product commercially marketed after February 15, 2007.
Manufacturers of electronic nicotine delivery systems (ENDS) or other noncombusted tobacco products that were on the market as of August 8, 2016, must submit a PMTA by August 8, 2022. Any new ENDS products that manufacturers seek to market after August 8, 2016 must receive a marketing order from FDA before it may be commercially marketed in the United States.
Submit online through the CTP Portal, an alternative to the existing FDA Electronic Submissions Gateway (ESG) WebTrader tool. The CTP Portal provides a convenient, secure online system for electronically submitting documents.
If you are unable to submit online, you can mail your submission to CTP's Document Control Center.
Upon receipt of an application, the FDA will determine if the application can be accepted and then filed for substantive review. FDA has regulations governing the agency’s determination of whether to accept a PMTA.
If the application is accepted, the FDA then will conduct a filing review to determine whether the application is complete, i.e., whether it contains all the items under Section 910(b)(1) of the FD&C Act and a required environmental analysis. If not, the application is incomplete, and FDA will refuse to file it.
If the application is complete, FDA will file the application and begin substantive review.
As part of its review, FDA may refer the applications to the Tobacco Product Scientific Advisory Committee (TPSAC). You may also request that FDA refer your application to TPSAC.
After completing its review, FDA intends to issue an order within 180 days of receipt of a complete PMTA submission indicating whether the new product may or may not be introduced or delivered for introduction to consumers.
FDA has published a guidance and a draft guidance for industry:
- Guidance: Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS) (2019)
- Draft Guidance: Applications for Premarket Review of New Tobacco Products (2011)
FDA has also presented webinars discussing this topic:
- Watch the 2016 webinar discussing the draft guidance "Premarket Tobacco Product Applications (PMTA) for Electronic Nicotine Delivery System (ENDS)."
Meetings are another mechanism to obtain information on specific questions regarding the PMTA process. See below for more information on meeting requests.
FDA encourages applicants to request meetings prior to submitting a PMTA.
For more information, please see FDA's Guidance: Meetings with Industry and Investigators on the Research and Development of Tobacco Products (2016).
This web content highlights provisions of the Food, Drug and Cosmetic Act (FD&C Act). It is not intended to be comprehensive or reflect FDA's interpretation of the Act. For complete information, you must read the entire law. For your convenience, the section number of the FD&C Act is referenced and relevant sections are linked to throughout the web content.
- Tobacco Control Act
- FDA Tobacco Compliance Webinars
- Modified Risk Tobacco Products Applications
- Small Business Assistance for Tobacco Product Industry
- Submit and Reference Tobacco Product Master Files
- CTP Ombudsman